pf-06459988
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02297425)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Epidermal growth factor receptorINHIBITOR
Epidermal growth factor receptor inhibitor
Epidermal growth factor receptor erbB1 inhibitor
Selective for T790M-containing EGFR
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1- Mol. weight
- 431.88 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3786098 ↗
Also known as
- pf-06459988
- pf-06459988
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02297425 | Phase 2 | Jan 1, 2015 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1